Pharma Awaits Rule on Combo Drugs in Medicare Price Negotiations

The pharmaceutical industry is seeking clarity on whether the Centers for Medicare & Medicaid Services will select drugs along with their newer subcutaneous versions for a government price negotiation program, hoping the agency drops the proposal in a pending rule under review by the White House.

A proposed regulation sitting at the Office of Management and Budget is likely to address whether the US government will select fixed-dose combination treatments for future rounds of the Medicare Drug Price Negotiation Program. The CMS sought to finalize the proposal in guidance last year, but dropped it and said it would address it ...